Loading...
Loading...
SRPT| Name | Value |
|---|---|
| Revenues | 258.4M |
| Cost of Revenue | 30.8M |
| Gross Profit | 227.6M |
| Operating Expense | 334.5M |
| Operating I/L | -106.8M |
| Other Income/Expense | 5.5M |
| Interest Income | 9.1M |
| Pretax | -101.3M |
| Income Tax Expense | 7.9M |
| Net Income/Loss | -109.2M |
Sarepta Therapeutics, Inc. is a biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases. Its flagship products, EXONDYS 51 and VYONDYS 53, treat Duchenne muscular dystrophy by targeting specific gene mutations. The company is also developing AMONDYS 45, SRP-5051, SRP-9001, and SRP-9003, utilizing exon-skipping technology and gene therapy programs. Sarepta has collaboration agreements with leading institutions and organizations. Its revenue is generated through the commercialization of its approved products and potential future sales of its pipeline candidates.
